Imunon (NASDAQ:IMNN) Shares Down 3.4% – Should You Sell?

Imunon, Inc. (NASDAQ:IMNN)’s stock price traded down 3.4% during trading on Monday. The stock traded as low as $0.98 and last traded at $0.9850. 93,790 shares traded hands during trading, a decline of 22% from the average daily volume of 120,872 shares. The stock had previously closed at $1.02.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a research note on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

Imunon Stock Performance

The company has a quick ratio of 1.82, a current ratio of 1.82 and a debt-to-equity ratio of 2.86. The stock has a 50 day simple moving average of $1.40 and a two-hundred day simple moving average of $1.93. The stock has a market capitalization of $6.70 million, a P/E ratio of -0.30 and a beta of 2.01.

Imunon (NASDAQ:IMNN) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.33. On average, equities analysts forecast that Imunon, Inc. will post -2.37 EPS for the current fiscal year.

About Imunon

Imunon, Inc is a clinical-stage biotechnology company focused on developing nucleic acid-based therapeutics for the treatment of cancer and other serious diseases. The company’s work centers on technologies designed to deliver genetic material to targeted tissues and stimulate immune responses against tumors.

Imunon’s lead program is GEN-1, an investigational DNA-based immunotherapy designed to produce interleukin-12 (IL-12) locally in the tumor environment. The company has studied GEN-1 primarily in combination with chemotherapy for gynecologic cancers, including advanced ovarian cancer, with the goal of enhancing the immune system’s ability to attack malignant cells while limiting systemic exposure to IL-12.

The company also develops proprietary delivery platforms, including its TheraPlas technology, which is intended to enable the delivery of DNA and other nucleic acid therapeutics.